Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. Ristau

Identification of a Highly Lethal V3+ TP53+ Subset in ALK+ Lung Adenocarcinoma

International Journal of Cancer

Cancer Research

Oncology

2018

English

Related publications

Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant

Journal of Thoracic Oncology

English

A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib

Journal of Thoracic Oncology

English

Concurrent Presence of ALK Rearrangement and MET Mutation in Lung Adenocarcinoma

Journal of Thoracic Oncology

English

Complete Pathological Response to Crizotinib in a Patient With ALK-rearranged Lung Adenocarcinoma

English

Uncommon Features of Surgically Resected ALK-positive Cavitary Lung Adenocarcinoma: A Case Report

Surgical Case Reports

2017

English

Identification of a Multidimensional Transcriptome Prognostic Signature for Lung Adenocarcinoma

Journal of Clinical Laboratory Analysis

Medical Laboratory Technology

Clinical Biochemistry

English

ALK Testing in Lung Adenocarcinoma: Technical Aspects to Improve FISH Evaluation in Daily Practice

Journal of Thoracic Oncology

English

ALK Fusion Protein Expression in Lung Adenocarcinoma and Its Correlation With EGFR Protein Expression

Madridge Journal of Oncogenesis

2018

English

Comment on ‘Testing for ALK Rearrangement in Lung Adenocarcinoma: A Multicenter Comparison of Immunohistochemistry and Fluorescent in Situ Hybridization’

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. Ristau

Identification of a Highly Lethal V3+ TP53+ Subset in ALK+ Lung Adenocarcinoma

Related publications

Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant

A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib

Concurrent Presence of ALK Rearrangement and MET Mutation in Lung Adenocarcinoma

Complete Pathological Response to Crizotinib in a Patient With ALK-rearranged Lung Adenocarcinoma

Uncommon Features of Surgically Resected ALK-positive Cavitary Lung Adenocarcinoma: A Case Report

Identification of a Multidimensional Transcriptome Prognostic Signature for Lung Adenocarcinoma

ALK Testing in Lung Adenocarcinoma: Technical Aspects to Improve FISH Evaluation in Daily Practice

ALK Fusion Protein Expression in Lung Adenocarcinoma and Its Correlation With EGFR Protein Expression

Comment on ‘Testing for ALK Rearrangement in Lung Adenocarcinoma: A Multicenter Comparison of Immunohistochemistry and Fluorescent in Situ Hybridization’